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Angiotensin converting enzyme (ACE) generates angiotensin
II from angiotensin I, which plays a critical role in the
pathophysiology of diabetic nephropathy. However, ACE2
generates angiotensin 1–7, which may protect the kidney by
attenuating the effects of angiotensin II, since deletion of the
Ace2 gene leads to glomerulosclerosis in mice, and
pharmacologic inhibition of ACE2 exacerbates experimental
diabetic nephropathy. We measured ACE2 and ACE
expression in renal biopsies of patients with kidney disease
due to type 2 diabetes to determine if the expression pattern
is specific to diabetic nephropathy. ACE2 and ACE mRNA
levels were measured by real-time PCR in laser
microdissected renal biopsies from 13 diabetic and 8 control
patients. ACE2 mRNA was significantly reduced by more than
half in both the glomeruli and proximal tubules of the
diabetic patients compared to controls, but ACE mRNA was
increased in both compartments. There was a significant
parallel decrease in ACE2 protein expression, determined by
immunohistochemistry, in proximal tubules, a pattern not
found in 12 patients with focal glomerulosclerosis or 10
patients with chronic allograft nephropathy. Our results
suggest that the kidney disease of patients with type 2
diabetes is associated with a reduction in ACE2 gene and
protein expression and this may contribute to the
progression of renal injury.
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The renin-angiotensin system (RAS) is important in the
pathophysiology of many progressive renal diseases including
diabetic nephropathy (DN), and blockade of the RAS system
with either angiotensin-converting enzyme (ACE) inhibition
or Ang II receptor blockade attenuates progression of
glomerular disease including DN.1–3 Angiotensin-converting
enzyme-2 (ACE2) is a recently discovered homologue of ACE
that regulates activity of the RAS by reducing Ang II levels
and increasing the generation of Ang 1–7, and therefore
expression of ACE2 in the kidney may be an important
determinant of injury.4 Microdissection studies of the rat
kidney have shown that ACE2 mRNA levels can be detected
in almost every segment of the nephron including the
glomerulus and the proximal tubule (but not the medullary
thick ascending limb).5 ACE2 is located along the apical
surface of proximal tubules,6 and in the glomerulus ACE2 is
expressed in podocytes and mesangial cells.7,8
Recent studies have shown that deletion of the Ace2 gene
leads to the development of de novo glomerulosclerosis in
mice and pharmacologic inhibition of ACE2 worsens
experimental DN,7,9,10 but there are limited data on the
expression of ACE2 in the kidneys of normal human subjects
and subjects with DN.8,11 In a recent report, Lely et al.8
studied ACE2 protein expression by immunohistochemistry
in the kidneys of patients with a variety of glomerular and
non-glomerular diseases. They observed neo-expression of
ACE2 protein in glomerular and peritubular capillary
endothelial cells, but DN constituted only a small minority
of the study patients, and disease-specific information on
ACE2 expression was not reported.8 Konoshita et al.11
measured ACE2 mRNA levels in whole-kidney biopsy cores
from subjects with diabetic and nondiabetic kidney disease.
They found that ACE2 mRNA levels were similar in the two
groups but no control subjects were included in the study.
Accordingly, the goal of the current study was to
determine if DN is associated with glomerular and tubular
changes in ACE2 gene and protein expression in subjects with
type 2 diabetes mellitus (DM) compared to control subjects
with normal kidney function. To test this hypothesis, we
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measured ACE2 mRNA levels with real-time PCR in laser-
captured glomeruli and proximal tubules from kidney biopsy
samples of control subjects and subjects with type 2 DM and
DN, and we assessed ACE2 protein expression in the kidney
with immunohistochemistry and computer-assisted image
analysis. To determine if the pattern of ACE2 expression is
specific to diabetes, we also compared ACE2 mRNA and
protein levels in microdissected kidney biopsies of subjects
with nondiabetic kidney disease: primary focal segmental
glomerulosclerosis (FSGS) and chronic allograft nephropathy
(CAN).
RESULTS
Patient and biopsy characteristics
The clinical parameters of study subjects are provided in
Table 1. Subjects with DN (n¼ 13) tended to be older, and
there was a higher ratio of male subjects in comparison with
control subjects (n¼ 8). As expected, subjects with DN had
higher hemoglobin A1C levels, and impaired renal function.
Pathologic review confirmed that all of the biopsies from
subjects with diabetes showed diffuse or diffuse and nodular
diabetic glomerulosclerosis with marked mesangial matrix
expansion, diffuse glomerular basement membrane thicken-
ing, and mild to moderate interstitial fibrosis. All of the
kidney biopsies from the potential living donors were normal
at the light microscopic level but five subjects had evidence of
thin glomerular basement membranes by electron micro-
scopy. Subjects did not have uncontrolled hypertension at the
time of biopsy. None of the control subjects had a history of
hypertension (data available for 6 of 8 subjects), and all of the
diabetic subjects had a history of hypertension (data available
for 7 of 13 subjects).
ACE2 and ACE gene expression
Laser capture microdissection of glomeruli and tubules was
performed on frozen sections. There was a 58% decrease in
the expression of ACE2 in the proximal tubules of subjects
with DN vs controls as quantified by real-time PCR
(Po0.05), and a 56% decrease in ACE2 gene expression in
the glomerular compartment (Po0.05) of biopsies from
patients with DN vs controls (Figure 1a). The abundance of
ACE2 mRNA was generally lower in the glomerular
compartment than in the tubular compartment in both
groups. As illustrated in Figure 1b, the expression of ACE was
twice as high in both the tubular and glomerular compart-
ment of subjects with DN vs control (Po0.05).
Effect of ACE inhibitor or angiotensin receptor blocker
treatment on ACE2 expression in the diabetic kidney
Seven of the thirteen diabetic subjects were treated with ACE
inhibitors or angiotensin receptor blocker at the time of the
renal biopsy, and therefore kidney ACE2 expression was
compared in the treated and untreated diabetic subjects
(Table 2). Median values for creatinine and proteinuria were
similar in the two groups of diabetic subjects and there were
no differences in glomerular or tubular expression of ACE2.
Fibrosis scores and gene expression
ACE2 and ACE expression were related to semiquantitative
scores of segmental glomerulosclerosis, global glomerulo-
sclerosis, and tubulointerstitial fibrosis in DM biopsies. We
did not find a relationship between gene expression and these
scores (data not shown).
Immunohistochemistry
Immunohistochemical analysis of ACE2 protein expression
was assessed in the same renal biopsies and mirrored the
Table 1 | Clinical parameters for the control and diabetic
subjects
Control (n=8)
Diabetic nephropathy
(n=13)
Age (years) 44±3 50±3
M:F 1:7 6:7
HbA1C (%)a 5.1±0.1 9.2±0.7*
Median SCr (mmol/l)
a 78 (52–115) 234 (45–530)*
Median eGFR
(ml/min/1.73 M2)a
87 (46–122) 29 (8–145)#
Median proteinuria (g/24 h)a 0.125 (0.1–1) 2.12 (0.19–12)*
% treated with ACEI (n) 13 (1) 54 (7)*
ACEI, angiotensin-converting enzyme inhibitor; eGFR, estimated glomerular filtration
rate based on the MDRD equation; F, female; HbA1C, hemoglobin A1C; M, male;
proteinuria, 24-h urine protein excretion; SCr, serum creatinine.
Data are presented as mean±s.e.m. or median and range.
*Po0.05 vs the control group as indicated; #P=0.06 vs the control group.
aBased on available data.
Glomerular
compartment
Proximal
tubular
compartment
Glomerular
compartment
Proximal
tubular
compartment
0
3
6 *
*
Controls
DN
*
*
DN
Controls
1.2
0.9
0.6
0.3
0
AC
E2
 m
RN
A 
(A
U)
AC
E 
m
RN
A 
(A
U)
Figure 1 | ACE2 and ACE mRNA expression in human diabetic
nephropathy (DN). Real-time RT-PCR from glomerular and
proximal tubular compartments, following laser capture
microdissection, from kidney biopsies of human subjects with DN
(n¼ 13) and controls (n¼ 8). (a) ACE2 mRNA expression. (b) ACE
mRNA expression. All real-time PCR data are expressed in arbitrary
units (AUs) corrected for GAPDH expression. *Po0.05 vs
nondiabetic controls.
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measures of mRNA expression (Figure 2a). Image analysis
confirmed a 60% reduction in immunoperoxidase staining
for ACE2 protein in the proximal tubules of the diabetic
kidney biopsies compared with the nondiabetic control
biopsies (Figure 2b). There was no significant relationship
between the tubular expression of ACE2 protein and the level
of proteinuria in the diabetic subjects by linear regression
analysis. The ACE2 protein levels were lower than the limit of
immunohistochemical detection in the glomerular compart-
ment in both groups.
ACE2 and ACE expression in FSGS and CAN
To determine if these changes in ACE2 and ACE expression
are unique to DN, gene expression was also measured in the
biopsies of subjects with FSGS and CAN. The clinical
characteristics of these subjects are provided in Table 3.
There was a significant difference in estimated glomerular
filtration rate (eGFR), serum creatinine, proteinuria, and
ACE inhibitor/angiotensin receptor blocker use across groups
(Po0.05). The results of measurement of ACE2 and ACE
mRNA expression are shown in Figure 3. There was no
significant difference in glomerular or tubular ACE2, or
glomerular ACE expression, in FSGS or CAN compared with
control biopsies (Figure 3). There was a trend toward
increased tubular ACE expression in FSGS but this did not
reach statistical significance. Similarly, there was no sig-
nificant difference in ACE2 protein expression as measured
by immunohistochemistry in either the tubular or glomer-
ular compartment (Figure 4). When subjects with either
FSGS or CAN were divided according to ACE inhibitor/
angiotensin receptor blocker use, there was an increase in the
tubular expression of ACE2 noted in subjects taking these
medications (2.15±1.34, n¼ 7 users vs 0.67±0.82, n¼ 14
nonusers, P¼ 0.03). There was no difference in glomerular
ACE2, tubular or glomerular ACE, when subjects were
analyzed according to medication use.
DISCUSSION
In this study we observed decreased ACE2 mRNA levels and
protein expression in kidneys of human subjects with DN
compared to nondiabetic healthy control subjects. The
decrease in ACE2 expression occurred in both glomeruli
and proximal tubule cells and the effect of DM on mRNA
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Figure 2 | Immunohistochemical staining for ACE2 protein in
renal biopsies in diabetic nephropathy (DN) and controls.
(a) A representative study of patient with DN and a normal live
human kidney donor, and (b) quantitative computer image
analysis of ACE2 immunohistochemistry staining intensity of
diabetic humans (n¼ 13) and controls (n¼ 8) (*Po0.05 vs
nondiabetic controls).
Table 3 | Clinical parameters for the control, FSGS, and CAN
subjects
Control (n=10) FSGS (n=12) CAN (n=10)
Age (years) 43.6±2.6 42.0±5.2 50.3±4.3
M:F 2:8 7:5 6:4
Median SCr
* 69 (53–97) 131 (45–273) 199 (122–270)
Median eGFR* 93.5 (56–124) 49.5 (22–132) 30 (18–50)
Median proteinuria* n/a 3.65 (0.8–10.4) o0.30 (o0.3–1)
% Rx ACEI (n)* 0 45.5 (5) 20 (2)
CAN, chronic allograft nephropathy; eGFR, estimated glomerular filtration rate based
on the MDRD equation; F, female; FSGS, focal segmental glomerulosclerosis;
M, male; proteinuria, 24-h urine protein excretion; Rx ACEI, treated with an
angiotensin-converting enzyme inhibitor or angiotensin receptor blocker treated;
SCr, serum creatinine.
Data are presented as mean±s.e.m. or median and range as indicated.
*Po0.05 across groups.
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Figure 3 | ACE2 and ACE mRNA expression in focal segmental
glomerulosclerosis (FSGS), chronic allograft nephropathy
(CAN), and control biopsies. (a) ACE2 mRNA expression. (b) ACE
mRNA expression. Real-time RT-PCR from proximal tubular and
glomerular compartments, following laser capture
microdissection from patients with FSGS (n¼ 12), CAN (n¼ 10),
and controls (n¼ 10). Results are expressed as arbitrary units (AUs)
corrected for GAPDH. There were no significant differences across
or between the three groups.
Table 2 | The effect of ACE inhibitor or angiotensin receptor
blocker treatment on ACE2 expression in diabetic subjects
No ACEI (n=6) ACEI (n=7)
Median SCr (mmol/l)
a 220 (45–274) 321 (56–530)
Median eGFR (ml/min/1.73 M2)a 30 (17–135) 18 (8–145)
Median proteinuria (g/24 h)a 2.18 (0.19–3.2) 2.17 (1.36–12)
Glomerular ACE2, mRNA (AU) 0.070±0.040 0.075±0.060
Tubular ACE2, mRNA (AU) 0.52±0.22 0.32±0.37
ACEI, angiotensin-converting enzyme inhibitor; AU, arbitrary unit; eGFR, estimated
glomerular filtration rate based on the MDRD equation; SCr, serum creatinine.
AU corrected for GAPDH expression. Data are presented as mean±s.e.m. or median
and range as indicated. There were no significant differences between the two
groups of diabetic subjects.
aBased on available data; proteinuria (24-h urine protein excretion).
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levels and protein levels was similar in both of these
compartments.
ACE2 is a monocarboxypeptidase that cleaves a single
amino acid from the C terminus of Ang I and Ang II, which
leads to the generation of Ang 1–9 and Ang 1–7, respectively.
Ang 1–7 has vasodilatory and antiproliferative effects, and it
antagonizes Ang-II-mediated cell signaling including trans-
forming growth factor-b 1 expression.12 Together with the
reports of gene deletion studies and pharmacologic ACE2
blockade,7,9,10,13,14 our findings on ACE2 expression in the
diabetic kidney are consistent with the notion that ACE2
serves a protective role in the kidney, and support the
hypothesis that reduced ACE2 expression (and activity) may
contribute to the development and progression of kidney
injury, including DN. However, the data do not establish a
causal relationship between ACE2 expression and DN nor the
mechanism(s) responsible for the decrease in ACE2.
In contrast to the change in ACE2 expression, ACE
expression increased in both the glomerular and proximal
tubule cells of the diabetic kidneys compared to the
control kidneys, in accord with previous observations by
Zimpelmann et al.15 in the kidneys of streptozotocin-induced
diabetic rats, and the observations of Ye et al.7 in the
glomeruli of diabetic db/db mice. It is possible that these
relative changes might lead to a shift in angiotensin peptide
processing toward generation of Ang II and away from the
generation of Ang 1–7 in the diabetic kidney, an effect that is
predicted to be deleterious. In support of this hypothesis,
Huang et al.16 reported that there was a relationship between
the development of DN and levels of ACE expression in
transgenic mice. We could not measure angiotensin peptides
in our kidney biopsy samples so the effect of the changes in
ACE2 and ACE expression on angiotensin peptide processing
remains speculative.
Table 4 summarizes the current literature regarding ACE2
expression and activity in experimental and clinical DN.
Tikellis et al.17 were the first to study ACE2 expression in rats
with streptozotocin-induced diabetes, a model of type 1 DM.
They reported that ACE2 mRNA and protein levels were
reduced by 50% in the renal tubules of diabetic rats, similar
to our findings, and they also observed that ACE2 expression
was mainly in the tubular compartment. In contrast to our
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Figure 4 | Immunohistochemical staining for ACE2 protein in renal biopsies in focal segmental glomerulosclerosis (FSGS),
chronic allograft nephropathy (CAN), and controls. (a) Representative study patients with idiopathic FSGS, CAN, and a normal live kidney
donor. (b) Quantitative computer image analysis of ACE2 immunohistochemistry staining intensity in biopsies of patients with FSGS
(n¼ 12), CAN (n¼ 10), and in controls (n¼ 10). There were no significant differences across or between the three groups.
Table 4 | Summary of available literature describing ACE2 expression in glomeruli and renal tubules in diabetic nephropathy
Glomerulus Proximal tubules/cortex
ACE2 mRNA ACE2 protein ACE2 mRNA ACE2 protein ACE2 activity
Human
Reich et al. k BD k k NA
Lely et al.8 NA m NA 2 NA
Konoshita et al.11 NA NA 2 NA NA
Animal models
Tikellis et al.17 Streptozotocin rats (type 1 DM) m m k k NA
Ye et al.7,19; Wyscocki et al.18db/db mice (type 2 DM) NA k 2 m m
Wysocki et al.18 Streptozotocin mice (type 1 DM) NA NA 2 m m
Wong et al.13 Akita mice (type 1 DM) NA NA m NA NA
k, decreased ACE2 expression; m, increased ACE2 expression;2, no significant difference in expression; BD, below detection limit; DM, diabetes mellitus; NA, not analyzed.
The results of the study reported herein and other human and rodent studies of renal ACE2 expression in diabetic nephropathy are summarized. Studies reporting mRNA
expression of whole cortex renal tissue were considered to represent the proximal tubular compartment for the purposes of this summary.
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results in human kidney biopsies, DM was associated with an
increase in glomerular ACE2 expression. Interestingly,
Wysocki et al.18 studied ACE2 expression and activity in
the kidney cortex of mice with streptozotocin-induced DM
and they reported that ACE2 protein expression and ACE2
activity were increased compared to nondiabetic mice.
Similar findings were reported in the db/db mouse, a model
of type 2 DM.18,19 Recently, the same group reported that
ACE2 immunostaining was reduced in the glomeruli of the
db/db mice compared to nondiabetic db/m mice.7 Taken
together, it is difficult to reconcile these observations on
ACE2 expression in experimental DM, and the effect of
diabetes may be specific for each model and dependent on
the stage of injury.
There are limited but incomplete data on ACE2 expression
in human DN. A study comparing ACE2 mRNA levels in the
biopsies of patients with diabetic and nondiabetic kidney
disease demonstrated no differences in ACE2 expression
across a wide range of disease categories.11 However, diabetic
subjects consisted only a small subset of the study subjects (8
of 74 subjects), gene expression was not compared with that
of a normal control group, and the mRNA levels were not
correlated with protein expression. Lely et al.8 reported that
ACE2 protein immunostaining was uniformly increased in
the glomeruli and peritubular capillaries in kidney biopsies
representing a variety of kidney diseases, including some
subjects with DN, however this was assessed semiquantita-
tively, and mRNA levels, which may be more sensitive given
the relatively low abundance of the protein, were not
assessed. Furthermore, the relative difference in ACE2
expression between DN and normal kidney biopsies was
not a specific focus of this study.8
The effect of blockade of the RAS on ACE2 expression in
the human kidney has not been well studied although Tikellis
et al.17 have examined the effect of ACE inhibitor treatment
on ACE2 expression in the kidneys of rats with streptozo-
tocin-induced DM. They reported that ACE2 mRNA levels
were low in the diabetic kidney and unaffected by treatment
with ramipril, in accord with our observations in the kidneys
of subjects with type 2 DM. They did report that ACE2
protein levels were markedly increased in association with
ramipril treatment (in contrast to the effect on mRNA levels)
in diabetic rats, but we did not observe any discordance
between measures of ACE2 mRNA expression and protein
expression in our kidney biopsy samples. Ferrario et al.20
reported studies of the effect of ACE inhibition, angiotensin
receptor blockade, and combination therapy on ACE2 mRNA
levels in the kidneys of normal rats. ACE2 mRNA levels were
not affected by any of the treatments.
To determine if the pattern of ACE2 and ACE expression
that we observed in the kidneys of subjects with DN was
specific for DN or might represent a generalized response to
kidney injury, we studied two separate groups of subjects
with kidney disease: FSGS and CAN. We chose FSGS because
like DN, it is also a glomerular disease marked by proteinuria;
we chose CAN as it represents a chronic progressive kidney
disease that is not glomerular in origin, and it is characterized
by prominent tubulointerstitial injury. We found that ACE2
and ACE mRNA levels were not different in the kidney
biopsies of subjects with FSGS or CAN compared to controls,
suggesting that decline in ACE2 expression is not a general
feature of kidney injury and that there is some specificity of
this response for DN. Interestingly, blockade of the RAS
(with ACE inhibitor/angiotensin receptor blocker) in subjects
with either FSGS or CAN was associated with an increase in
the tubular expression of ACE2, and it is tempting to
speculate that ACE inhibitor/angiotensin receptor blocker use
may alter ACE2 levels in subjects without diabetes.
The strengths of the current study are that we compared
ACE2 and ACE expression in the kidney of subjects with type
2 DM with the kidneys of healthy control subjects, and we
localized expression at the mRNA level by performing laser
capture microscopy of the glomeruli and proximal tubule
cells. We also related ACE2 mRNA levels with protein
expression by immunohistochemistry and image analysis.
However, this report is descriptive, and we did not correlate
measures of mRNA and protein expression levels with ACE2
activity in the kidney or with measures of angiotensin
peptides. In addition, gender and hypertension may be
confounding variables in our analysis. Women were over-
represented in our control group, largely because of the fact
that our control subjects were potential living kidney donors,
which tend to be women at our center.21 A history of
hypertension was prominent in our diabetic subjects but we
could not correct our analysis for blood pressure levels.
In conclusion, ACE2 mRNA levels and protein expression
decrease in the proximal tubules of patients with DN
compared with nondiabetic healthy control subjects, and a
similar trend is observed in the glomeruli. ACE2 expression is
relatively low in human glomeruli compared to the proximal
tubule cells in both normal and diabetic kidneys, and
treatment with an ACE inhibitor does not affect ACE2
expression in the diabetic kidney. Finally, the pattern of
decreased ACE2 and increased ACE expression was not
observed in the biopsies of subjects with FSGS or CAN. In
subjects with diabetes, the combination of effects of altered
ACE2 and ACE expression may contribute to the progression
of DN.
MATERIALS AND METHODS
Renal biopsies
Renal biopsies had been performed as part of routine clinical
diagnostic investigation. Informed consent was obtained
from patients for use of archived human biopsy material and
chart review in accord with institutional research ethics
board review. The diabetes samples were obtained from
patients with documented type 2 diabetes and a pathologic
diagnosis of DN. Control tissues were obtained from healthy
potential live transplant donors who were referred for biopsy
because of microscopic hematuria, who had normal renal
function and no proteinuria. Control renal biopsies were
either normal or showed thin basement membranes accord-
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ing to pathologist review. Routine immunofluorescence
microscopy of these biopsy samples showed negative staining
for immunoglobulins and complement.
Laser capture microdissection and real-time PCR
Snap-frozen renal biopsies stored at 80 1C were cut at 8 mm
and stained with HistoGene (Arcturus, Mountainview, CA,
USA) and laser microdissected using the Pixcell IIe
(Arcturus). Glomerular profiles and kidney proximal tubules
were identified by an experienced renal pathologist (AMH),
separately dissected, and collected for mRNA extraction. The
mRNA was extracted using the PicoPure kit (Arcturus) and
first-strand cDNA synthesis was performed using the Sensi-
script RT Kit (Qiagen, Valencia, CA, USA). The cDNA was
used undiluted for TaqMan real-time PCR on an Applied
Biosystems 7900 machine. The ACE2 gene expression was
expressed as a ratio of ACE2/GAPDH (glyceraldehyde-3-
phosphate dehydrogenase) housekeeping gene. There was no
significant difference in GAPDH levels in disease samples
compared to control samples, and we have found that
GAPDH is a more consistent reference mRNA than 18S or b-
actin. Primers and probe for amplification were as follows—
ACE2: CATTGGAGCAAGTGTTGGATCTT (forward), GAG
CTAATGCATGCCATTCTCA (reverse), CTTGCAACACCAG
TTCCCAGGCA (probe); ACE: CCGAAATACGTGGAACT
CATCAA (forward), CACGAGTCCCCTGCATCTACA (reverse),
CAGGCTGCCCGGCTCAATGG (probe). GAPDH primer
sets were designed as follows: GAAGGTGAAGGTCGGAGTC
(forward), GAAGATGGTGATGGGATTTC (reverse), and CAA
GCTTCCCGTTCTCAGCC (probe). In addition, GAPDH
primers were also purchased from Applied Biosystems.
Immunohistochemistry
Formalin-fixed paraffin-embedded sections from the same
renal biopsy were cut at 3mm followed by heat-induced
antigen retrieval. Sections were incubated with monoclonal
anti-ACE2 (1:400) antibodies.14 To eliminate any potential
nonspecific biotin activity, slides were stained with a
secondary anti-mouse antibody using the EnVision system
(Dako). Endogenous peroxidase activity was prevented by
pretreating with 3% hydrogen peroxide. Image-Pro Plus
(Media Cybernetics) computer image analysis software was
used to analyze brown staining pixel density and quantify
protein levels. Negative controls with irrelevant primary
antibody and no primary antibody were performed.
Calculations and statistics
The eGFR was calculated using the abbreviated Modification
of Diet in Renal Disease equation.22,23 The distribution of
clinical data was visualized and summary data are expressed
as mean±standard error or median and range as indicated.
Differences in means were analyzed using nonparametric
tests when data were not normally distributed. Gene and
protein expression data were analyzed using both parametric
(for example, analysis of variance, with Levene’s test of the
assumption of equal variance) and nonparametric (that is,
Wilcoxon) analyses, and similar results were obtained using
both approaches. Linear regression was used to relate the
ACE2 expression to the level of proteinuria and fibrosis in the
diabetic subjects. All statistical tests were performed using
SAS (SAS Institute, Cary, NC, USA), and two-tailed P-values
are provided.
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